Émilie Agavnian

Technicien(ne) IPC

Voir les publications Voir le mail Tel : +33 (0)4 91 22 33 33

Plateforme

Histo-Pathologie Expérimentale

Sep 2018 Oncotarget

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer.

Guerin M, Gonçalves A, Toiron Y, Baudelet E, Pophillat M, Granjeaud S, Fourquet P, Jacot W, Tarpin C, Sabatier R, Agavnian E, Finetti P, Adelaide J, Birnbaum D, Ginestier C, Charafe-Jauffret E, Viens P, Bertucci F, Borg JP, Camoin L

Dec 2017 International journal of molecular sciences

Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value.

Doghri R, Manai M, Finetti P, Driss M, Agavnian E, Lopez M, Elghardallou M, Charafe-Jauffret E, Manai M, Chaffanet M, Birnbaum D, Mrad K, Bertucci F

Mar 2017 Scientific reports

Septin 9_i2 is downregulated in tumors, impairs cancer cell migration and alters subnuclear actin filaments.

Verdier-Pinard P, Salaun D, Bouguenina H, Shimada S, Pophillat M, Audebert S, Agavnian E, Coslet S, Charafe-Jauffret E, Tachibana T, Badache A